Hans-Peter Stoll

Showing 1-10 of 10 articles

Coronary interventions

Efficacy of Thin- Versus Thick-Strut Polymer-Free Biolimus-Eluting Stents: the Biofreedom QCA Randomized Trial

Sabaté M, Okkels-Jensen L, Tilsted H, Moreno R, García del Blanco B, Macaya C, Perez de Prado A, Cequier A, Pérez-Fuentes P, Schütte D, Costa R, Stoll H, Lassen J

January 13, 2021 | 10.4244/EIJ-D-20-01162

Impact of ticagrelor monotherapy on two-year clinical outcomes in patients with long stenting: a post hoc analysis of the GLOBAL LEADERS trial

Takahashi K, Chichareon P, Modolo R, Kogame N, Chang C, Tomaniak M, Moschovitis A, Curzen N, Haude M, Jung W, Holmvang L, Garg S, Tijssen J, Wykrzykowska J, de Winter R, Hamm C, Steg P, Stoll H, Onuma Y, Valgimigli M, Vranckx P, Windecker S, Serruys P

October 23, 2020 | 10.4244/EIJ-D-19-00498

Coronary interventions

Drug-Coated Stents Versus Bare-Metal Stents in Academic Research Consortium-Defined High Bleeding Risk Patients

Marquis-Gravel G, Urban P, Copt S, Capodanno D, Pocock S, Sadozai Slama S, Stoll H, Tanguay J-F, Mehran R, Leon M, Rao SV, Morice M, Krucoff M

August 25, 2020 | 10.4244/EIJ-D-20-00749

Coronary interventions

Establishment of healing profile and neointimal transformation in the new polymer-free biolimus A9-coated coronary stent by longitudinal sequential optical coherence tomography assessments: the EGO-BIOFREEDOM study

Lee WLS, Tam FCC, Chan KKW, Lam S, Kong S-L, Shea CP, Wong MKL, Wong AYT, Yung ASY, Zhang L-W, Lam Y-M, Mintz G, Costa R, Stoll H, Maehara A

September 20, 2018 | 10.4244/EIJ-D-18-00061

Biolimus A9 polymer-free coated stents in high bleeding risk patients undergoing complex PCI: evidence from the LEADERS FREE randomised clinical trial

Lipiecki J, Brunel P, Morice M, Roguelov C, Walsh S, Richardt G, Eerdmans P, Zambahari R, Berland J, Copt S, Stoll H, Urban P

July 20, 2018 | 10.4244/EIJ-D-18-00293

Two-year outcomes of high bleeding risk patients with acute coronary syndrome after Biolimus A9 polymer-free drug-coated stents: a LEADERS FREE substudy

Jensen C, Naber C, Urban P, Ong PJ, Valdés Chávarri M, Abizaid A, Pocock S, Fabbiocchi F, Dubois C, Copt S, Stoll H, Morice M

March 20, 2018 | 10.4244/EIJ-D-17-00720

Outcomes in patients undergoing multivessel percutaneous coronary intervention using sirolimus-eluting stents: a report from the e-SELECT registry

Cuculi F, Banning A, Abizaid A, Bartorelli A, Baux A, Dzavik V, Ellis SG, Gao R, Holmes D, Jeong M, Legrand V, Neumann F, Nyakern M, Spaulding C, Stoll H, Worthley S, Urban P

December 30, 2011 | 10.4244/EIJV7I8A152

Effect of gender differences on early and mid-term clinical outcome after percutaneous or surgical coronary revascularisation in patients with multivessel coronary artery disease: Insights from ARTS I and ARTS II

Vaina S, Voudris V, Morice M, De Bruyne B, Colombo A, Macaya C, Richardt G, Fajadet J, Hamm C, Schuijer M, Macours N, Stoll H, Cokkinos D, Stefanadis C, Serruys P

January 20, 2009

Three-year follow-up of the ARTS-II# – Sirolimus-eluting stents for the treatment of patients with multivessel coronary artery disease

Serruys P, Daemen J, Morice M, De Bruyne B, Colombo A, Macaya C, Richardt G, Fajadet J, Hamm C, Dawkins K, Vranckx P, Bressers M, van Domburg R, Schuijer M, Wittebols K, Pieters M, Stoll H

January 20, 2008

One-year results of coronary revascularization in diabetic patients with multivessel coronary artery disease.

Macaya C, Garcia-Garcia H, Colombo A, Morice M, Legrand V, Kuck K, Sheiban I, Suttorp MJ, Carrié D, Vrolix M, Wittebols K, Stoll H, Donohoe D, Bressers M, Serruys P

May 20, 2006

Latest news

NEW ISSUE

Infective Endocarditis & TAVI; Cerebral Protection Devices; IVUS Assessment in ViV-TAVI, Mini Focus on Antithrombotic Therapy …

February 19, 2021

News

Don’t Miss #EIJOnAir 2nd Edition!

Elective cardiac invasive procedures during the COVID-19 outbreak

March 4, 2021

Ahead of Print

MitraClip for a range of LV dysfunction and secondary MR

Stamatios Lerakis et al.

March 2, 2021

Editorial

Thrombolysis in ST-elevation myocardial infarction is not dead

Petr Kala et al.

March 2, 2021

SCOPE 2, COACT 1 year, FORZA, COMPARE CRUSH

(Thanks to the support of Biotronik)

February 28, 2021

JAA

This Week's JAA's: Impact of crossing strategy on CTO recanalisation outcomes and more...

March 2, 2021

Guidance Papers

Guidelines, consensus & position papers